Celltrion Expands Biosimilar Portfolio in the European Union Following European Commission Approval of Two Biosimilars

Contributed by: Business Wire

Logo

Tags

Science

Biotechnology

Research

Pharmaceutical

Optical

General Health

Health

Clinical Trials

biosimilars

More Like This

Celltrion Receives Positive CHMP Opinion for Three Biosimilars in the European Union

Celltrion receives European Commission approval of Omlyclo® (CT-P39), the first and only omalizumab biosimilar approved in Europe

European Commission approves Celltrion’s SteQeyma® (CT-P43), a biosimilar to Stelara® (ustekinumab), for the treatment of multiple chronic inflammatory diseases

Samsung Bioepis Gains European Commission (EC) Approval for Denosumab Biosimilar (OBODENCE™, XBRYK™)

Celltrion showcases promising results in phase III study for CT-P47, a biosimilar candidate of RoActemra® (tocilizumab) in patients with rheumatoid arthritis (RA) at EULAR 2024

Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14

Biocytogen/Eucure Biopharma to Present Complete Clinical Data from YH003 (anti-CD40 mAb) Phase I Trial at ESMO 2023